Pregabalin and Duloxetine in Heart Disease

Introduction to Medication Use in Heart Disease

The American Heart Association and European Heart Society suggest that neither pregabalin nor duloxetine are absolutely contraindicated in heart disease, but both require careful consideration and monitoring based on specific cardiac conditions and risk factors 1, 2

Duloxetine does not produce clinically important electrocardiographic changes or blood pressure alterations in most patients and can be used in cardiac disease with appropriate precautions, as recommended by the American College of Cardiology 1
The European Heart Society warns that a combination of duloxetine with other QT-prolonging medications can lead to severe QT prolongation and ventricular fibrillation, particularly in patients with multiple risk factors such as age >65 years, pre-existing cardiovascular disease, bradycardia, female sex, electrolyte abnormalities, and concurrent QT-prolonging drugs 2, 3
Before prescribing duloxetine in cardiac patients, it is recommended to assess for cumulative risk factors and consider baseline ECG if multiple risks are present, according to the European Heart Society 2, 3
In patients with heart failure or significant cardiac disease, starting duloxetine at 30 mg daily for one week before increasing to 60 mg daily can help minimize adverse effects, as suggested by the American College of Cardiology and other guideline societies 1, 4

The American Heart Association recommends that duloxetine can be used in stable heart disease but requires ECG screening when combined with other QT-prolonging agents, monitoring for orthostatic hypotension, and avoidance in patients with recent MI or unstable coronary disease 1, 2
Pregabalin is preferred over duloxetine for neuropathic pain in dilated cardiomyopathy and most cardiac conditions due to minimal direct cardiac effects, but it should be avoided in NYHA Class III-IV heart failure and monitored closely for edema, weight gain, and electrolyte disturbances, as recommended by the European Heart Society 5

For stable cardiac disease without heart failure, both medications can be used with standard monitoring, according to the American College of Cardiology and the European Heart Society 1, 5
If ≥2 risk factors for QT prolongation are present, obtaining a baseline ECG before starting either medication is recommended by the European Heart Society 2, 3
Monitoring protocols for pregabalin include checking for peripheral edema, weight gain, and worsening heart failure symptoms, as well as assessing electrolytes, especially potassium, if using with other medications that affect electrolytes, as suggested by guideline societies 5
Duloxetine dosing should start at 30 mg once daily for one week, then increase to 60 mg once daily, with a maximum of 60 mg twice daily, according to the American College of Cardiology and other guideline societies 1, 4

Never combine multiple QT-prolonging medications without ECG monitoring and electrolyte assessment, as warned by the European Heart Society 2, 3
Do not overlook pregabalin-induced hypokalemia as a contributor to cardiac arrhythmias, as noted by the European Heart Society 2, 3